Esperion Therapeutics ESPR
$ 2.49
3.32%
Quarterly report 2024-Q3
added 11-07-2024
Country |
USA |
IPO year |
2013 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Mr. Timothy Mayleben |
Employees in the company |
193 |
Shares |
103 M |
Market Cap[1] |
$ 257 M |
EBITDA (LTM) |
$ -185 M |
P/E (LTM) |
-4.29 |
P/S (LTM) |
0.73 |
EPS (LTM) |
-0.49 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.